Persongen Biotherapeutics (suzhou) Co., Ltd.

This study tests a new treatment called PA3-17 for people with a type of blood cancer (T-lymphoblastic leukemia/lymphoma) that has come back or not responded to other treatments. The therapy uses the patient's own immune cells, modified to attack cancer cells. About 100 adults wi…

This early-stage trial tests an experimental cell therapy called UTAA07 in 15 adults with CD7-positive blood cancers that have come back or not responded to standard treatment. The main goals are to check safety and find the right dose. Participants receive a single injection and…

This early study tests a new treatment called LV009 injection in 10 adults whose blood cancers (certain types of lymphoma or leukemia) have returned or not responded to standard therapy. The main goal is to check if the treatment is safe. Participants receive the injection and ar…

This early-phase study tests a new treatment called LV009 injection for people with certain blood cancers (non-Hodgkin lymphoma and acute lymphoblastic leukemia) that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified …